The articles in this treatise have detailed the tremendous advances occurring on multiple fronts in attempting to assess the impact of new genetic technologies in obstetrics and gynecology. The focus of technological development has shifted from procedural to the laboratory, and the methodology of testing has shifted in large part from biochemical to molecularly based. With the continued
explosion of genetic technology, the number of disorders amenable to screening, diagnosis, and treatment is expanding geometrically. The completion of human genome project will lead to the identification of thousands of new genes, many of which may eventually be possible candidates for screening and treatment programs.
The emergency field of proteomics will be the focus of attention for perhaps the next decade; understanding gene products will be the next step toward tailoring therapies to maximize effectiveness to the individual while avoiding catastrophes from genetically predisposed toxicities. The use of these new methods will bring technology closer to the forefront in the general practice of obstetrics and gynecology.
Historically, the demand for new technologies has been a function of both the de-velopment of technology to allow such uses and of the demand created in response based on population incidence and the severity of the disorder. 1 Mass population-based screening has long been performed within the field of obstetrics and gynecology. 2 The technologies presented here, whether invasive tests, laboratory diagnostic tests, or screening tests, all have improved the ability to verify the health of both mother and fetus. It is only through the contributions of new biophysical 1 (eg, ultrasound), biochemical (eg, PAPPA), and molecular tests that dramatic progress has been possible. 3, 4 There are also marked variances in test acceptance and utilization as a function of ethnicity, religion, and geography. Particularly as the human genome project begins to have a demonstrable impact on the day-today practice of obstetrics and gynecology and genetics, how patients hear the information and how they internalize it will become of paramount importance. It is critical that Tuskeegee and other travesties of justice never happen again and do not hinder the availability of technology to minority groups. 5 We are just beginning to realize the potential of technological creativity. Moving "newborn" screening prenatally into even to the first trimester will be a perfect example. 4, 5 Newborn screening for disorders such as phenylketonuria has been routine and in fact the law in most of the United States for many years. 1, 6 However, diagnosis in the newborn is to some degree like "locking the barn door after the horse has been stolen."
The major difference between obstetrical screening and neonatal screening for genetic disorders is that in most jurisdictions, neonatal screening is not only sanctioned but also mandated by law. 3 Obstetrical screening is voluntary and requires informed consent discussions, and its utilization varies markedly among patient populations.
Much more than termination can also be done for the fetus if genetic screening and diagnosis could be accomplished early in the pregnancy rather than after birth. 7 First of all, diagnosis in the first trimester would allow couples who discover that the fetus has a serious genetic disorder to consider whether they wish to continue the pregnancy. In selected cases, there will be the possibility of treating these disorders in utero to either ameliorate or even cure certain genetic diseases.
For example, pharmacologic therapy is effective in the treatment of congenital adrenal hyperplasia, with the prevention of masculinization of external female genitalia in such cases. 8 Hematopoietic stem cell therapy has proven effective in the treatment of severe combined immunodeficiency disorder. 9 Treatment of other disorders has been attempted without success so far. We hope there will be success in the treatment of many inborn errors of metabolism and hematologic and other immunodeficiencies.
Linear array technologies will permit hundreds of thousands of reactions to be performed on the same specimen, so the concerns raised in the previous section should be able to be overcome. Array technology will not only radically change invasive prenatal diagnosis but also should (once the logistics, costs, and necessity for appropriate counseling have been worked out) extend the benefits of these molecular diagnoses to the obstetrical populations at large. 10 Invasive prenatal diagnosis using mo-lecular techniques has developed rapidly in the past decade, using amniotic fluid cells, chorionic villi, or fetal blood. 11 Obviously, all of these procedures are invasive and can be performed on only a small percentage of the population. Recent advances in isolating fetal cells that leak through into the maternal circulation suggest that this will be a screening technique of very high specificity for aneuploidy. 11 Although the data are still very preliminary, it appears as if for mendelian disorders the technology may prove diagnostic. 12 Over the course of the next decade, it is likely that many of the tests currently performed in the newborn period will be able to be accomplished in the early or midgestational period. 13 As such, there would be no reason to wait because of the advantages of reproductive choice and fetal therapy. Managing the shift from the nursery to obstetrical care will clearly be fraught with technical challenges, but it is the mindset of both physicians and patients that will have to be addressed in order for the transition to be successful.
On the nonpregnancy (ie, gynecologic and non-reproductive system medical) side, the identification of patients at risk for disease continues to expand geometrically. The full implications of the human genome project will be able to be understood only after many years. There will be clearly a gradual phase-in of technologies dealing with specific disease states rather than a sudden implementation of massive screening for hundreds of diseases at once. The United States, for example, is just beginning to grapple with mass-scale cystic fibrosis testing and screening. Fragile X is likely next. There are complex medical, legal, political, and ethical issues that are likely to produce a quagmire of lawsuits, exposures, economic analyses, and unforeseen pathways of activities.
Fortunately, with each new model testing system added upon existing ones, the process should become easier, less expensive, and simpler. Similarly, the standards in the Future Directions industry should become better understood, with the reduction of roadblocks (physical, economic, and legal) to new technologies. It is reasonable to believe that a massive educational program for both professionals and the lay public will be required to facilitate the transition.
Rather than fearing the advances that can produce voluminous amounts of genetic information, we as a pluralistic society have to recognize that there will be no monolithic response to the onslaught of information. How we allow information to be incorporated into society will help determine how such information can be used for societal and personal gain while minimizing the political overlay that has clouded many new technologies, particularly the reproductive ones. No one in this issue claims to have the answers; we are currently much better at asking unanswerable questions. Asking them, however, is the first step to finding reasonable conclusions.
